COMMUNIQUÉS West-GlobeNewswire

Sanofi : Déclaration des transactions sur actions propres
29/01/2018
Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/c8d27e2e-859c-40f7-9b2c-ea4b2c7d0c71
Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
29/01/2018
Company announcement Orphazyme A/S No. 02/2018 Copenhagen, Denmark, January 29, 2018 – Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, [...]
Pressure BioSciences, Inc. CEO, Ric Schumacher, Rejoins “Stock Day”, Very Optimistic About His Company’s Growth and Success in 2018 and Beyond
29/01/2018
PHOENIX, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Mr. Richard T. Schumacher, CEO and President of Pressure BioSciences, Inc. (OTCQB:PBIO) (the “Company”) returns to the “Stock Day” podcast for the first time since the Company’ [...]
ProCare Pain Solutions Publishes New Research Exploring Effects of Fibromyalgia on Chronic Pain Population
29/01/2018
MELVILLE, N.Y., Jan. 29, 2018 (GLOBE NEWSWIRE) -- ProCare Pain Solutions , a division of North American Partners in Anesthesia (NAPA) announced today that an innovative research study it conducted in 2016 and 2017 has [...]
Ossur Hf : Transactions in relation to share buyback program
29/01/2018
Announcement from Össur hf. No. 6/2018 Reykjavík, 29 January 2018 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
29/01/2018
COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’ [...]
Scapa Healthcare Introduces Low Trauma Hydrocolloid Adhesive for Sensitive Skin Applications
29/01/2018
WINDSOR, Conn., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Scapa Healthcare, a leading strategic outsource partner of skin friendly turn-key solutions, today announced the availability of Scapa Soft-Pro® Low Trauma Hydrocolloid [...]
Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/01/2018
REDWOOD CITY, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock at a public [...]
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
29/01/2018
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok [...]
Advantis Corp Expanding Into Colorado, California Nears Packaging Capacity With New Machine; Pre Orders for New Sizes Escalate Quickly
29/01/2018
NEWPORT BEACH, CA , Jan. 29, 2018 (GLOBE NEWSWIRE) -- ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it is finalizing an agreement to provide Amster-Can and other Advantis branded products to a licensed [...]
NYC Plastic Surgeon Cautions Against Winter Binge Tanning And Its Damaging Effects
29/01/2018
New York, New York, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Dr. Darrick E. Antell , a top plastic surgeon in NYC, warns against the damaging effects the sun can have when traveling in the winter months due to a phenomenon [...]
InstaLipo™ Reduces Stubborn Fat Non-Surgically!
29/01/2018
New York City, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Are you struggling to lose those extra inches off your waist, hips, thighs, or buttocks? NYC plastic surgeon Dr. Sharon Giese is now offering InstaLipo™ – the latest non- [...]
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
29/01/2018
LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the human gut microbiome to treat [...]
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
29/01/2018
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update: The Confidential [...]
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer
29/01/2018
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- – Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced [...]
DiaMedica to Present at the 14th Annual Noble Investor Conference
29/01/2018
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital Markets’ Fourteenth Annual [...]
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
29/01/2018
First gene therapy RMAT designation for Epidermolysis Bullosa Enables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO [...]
Hemispherx to Present at the BIO CEO & Investor Conference
29/01/2018
ORLANDO, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO & Investor Conference on [...]
Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/01/2018
EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced the closing of its previously announced underwritten public offering of its common stock. Adamas sold 3, [...]

Pages